S&P 500
Nasdaq
Dow Jones
NVDA
AAPL
TSLA
MSFT
BTC-USD
15-min delayed
Live
Home Market News Price Targets Penny Stocks Crypto Economy Commodities Education
Stocks About Contact

Regeneron Pharmaceuticals Inc

REGN XNAS
$612.50 -0.56 (-0.09%) ▼ 15-min delayed
Open
N/A
High
N/A
Low
N/A
Volume
N/A
Market Cap
$63.95B

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 15.4K Website →

Key Financials

Period Revenue Net Income EPS
Q1 2026 $3.61B $727.20M $6.99
FY 2025 $14.34B $4.50B $43.07
Q3 2025 $3.75B $1.46B $14.09
Q2 2025 $3.68B $1.39B $13.24

Get REGN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Regeneron Pharmaceuticals Inc.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.